Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

110.60 -2.11 (-1.87%)
Streaming Delayed Price Updated: 9:52 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’
Things got murkier at the FDA’s drug evaluation agency as its acting director stepped down, alleging that a new drug approval program injected politics, superseding decisions based on science. 
Via Stocktwits
Topics Lawsuit
Top 6 ETFs To Watch As Wall Street's Strongest Six Months Begin
As markets enter their strongest stretch, ETFs tied to AI, banking, and healthcare could shine. Here's where investors are finding fresh momentum. 
Via Benzinga
Topics Artificial Intelligence ETFs
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles
Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event. 
Via Benzinga
Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today
Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share. 
Via Stocktwits
Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral
Via Stocktwits
White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report
Via Stocktwits
Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts
The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures
SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures. 
Via Benzinga
4 Biotech Stocks Seeing Explosive Momentum Gains
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be... 
Via Benzinga
Topics ETFs Stocks
How Trump's Shutdown Standoff Could Hand Health-Care ETFs A Lifeline
Trump's comments on health-care negotiations with Democrats can put ETFs like XLV, IHF, and XHS back on investors' radar as Washington's shutdown drags on. 
Via Benzinga
Topics ETFs Government
SciSparc And AutoMax Call Off Merger
SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation. 
Via Benzinga
Eli Lilly Stock Jumps As Trump’s Drug Price Crackdown Spurs Sector Rally; Analysts Say Pfizer Deal Sets Template For Big Pharma
Via Stocktwits
Topics Government
Pharma Tariffs Back In Spotlight On New Trump Threat
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America
Via Stocktwits
Topics Government
uniQure Stock Rises Pre-Market After Investigational Huntington’s Disease Drug Slows Disease In Trial
The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale. 
Via Stocktwits
CrowdStrike, SoFi, Clearway Energy And More: CNBC's 'Final Trades'
Experts on CNBC's Halftime Report discussed top trades for the day. SoFi hit an all-time high, Clearway Energy has strong dividend yield, CrowdStrike rose sharply, and SPDR S&P Biotech ETF gained... 
Via Benzinga
Topics ETFs Stocks
As the Fed Pivots, These 3 ETFs Are Positioned to Outperform
With the Fed pivoting from inflation fighter to growth supporter, these three ETFs offer the best leverage to falling rates. 
Via The Motley Fool
Topics ETFs Economy
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy.
The tariffs will impact products imported from Europe, the Trump administration said late Thursday. 
Via Investor's Business Daily
Topics ETFs Government Intellectual Property
Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn
President Donald Trump said late Tuesday his administration will begin implementing pharmaceutical tariffs next month. 
Via Investor's Business Daily
Topics ETFs Government World Trade
Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs
President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon." 
Via Investor's Business Daily
Topics ETFs Economy Government
Avadel Pharmaceuticals Under Fire? Investor Reportedly Demands Board Ouster, Sale Talks, $1B In Damages
ASL Strategic Value Fund plans to vote its $15 million stake against all Avadel board nominees at the July meeting and is pushing for contingent-value rights tied to potential legal payouts, according... 
Via Stocktwits
Topics ETFs Intellectual Property
Capricor Therapeutics Says FDA May Not Hold Advisory Committee Meeting For DMD Therapy Approval: Stock Soars But Analyst Issues Warning
The FDA has indicated that an advisory committee meeting is not required at this time, the company said, while adding that its application for Deramiocel approval remains under priority review. 
Via Stocktwits
Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel Data
Capricor on Friday announced positive four-year safety and efficacy results from its ongoing mid-stage study of its cell therapy Deramiocel, which failed to cheer investors. 
Via Stocktwits
FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’
Capricor expressed confidence that the facility will meet the necessary requirements to support product licensure and commercial launch, pending approval. 
Via Stocktwits
Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation
Summit now intends to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration seeking approval for Ivonescimab plus chemotherapy based on the results of the trial. 
Via Stocktwits
Topics Lawsuit Regulatory Compliance
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence
The clinical-stage immunology company reported a net loss of $0.64 per share for the quarter, lower than an estimated loss of $0.72 per share. 
Via Stocktwits
Hedge Funds Are Building A Towering Wall Of Bets Against Stocks
After a sharp 23% rebound in the S&P 500 since April, hedge funds are now stacking record levels of bearish bets against stocks as investors question the staying power of the tariff-relief rally. 
Via Benzinga
Here's How Trump Plans To Tackle Drug Prices, And Why It Might Not Work
The Trump administration unveiled the first details Tuesday on how it plans to lower drug prices "drastically" in the U.S. 
Via Investor's Business Daily
Topics ETFs Government
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.